ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Antiaging firm Elevian launches

by Lisa M. Jarvis
September 15, 2018 | APPEARED IN VOLUME 96, ISSUE 37

Elevian has launched with $5.5 million in seed funding to pursue regenerative medicines for aging and age-related diseases. Based on work done in the labs of its scientific cofounder, Harvard University professor Amy Wagers, the biotech is developing therapeutics that increase the activity of growth-differentiating factor 11, a circulating factor that when given to mice elicits the regenerative benefits of young blood. Enhancing GDF11 levels could treat diseases such as Alzheimer’s, type 2 diabetes, and age-related muscle disorders, Elevian says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment